Impact of 3T multiparametric MRI and FDG-PET-CT in the evaluation of occult primary cancer with cervical node metastasis
Tóm tắt
This study aimed to determine the ability of multimodal evaluation with multiparametric 3T-MRI (MPMRI) and positron emission tomography - computed tomography (PET/CT) to detect cancer of unknown primary origin (CUP) with neck lymph node (LN) metastasis. The study group comprised 38 retrospectively analysed consecutive patients with LN metastasis in the head and neck (HN) region without known primary tumours (PTs). Statistical values of 3T-MRI and of FDG-PET/CT scans were evaluated. Of the 38 CUPs, conventional native T1-, T2-weighted and STIR sequences detected 6 PTs. Native sequences plus diffusion-weighted imaging (DWI) found 14-, and with fat suppression contrast-enhanced T1-weighted measurement as well as with the complex MPMRI found 15 primaries and with PET/CT 17 CUPs could be evaluated, respectively. The detection rates were 15.8, 36.8, 39.5, 39.5 and 44.7 % for conventional native MRI, native plus DWI, native with contrast-enhanced MRI (CE-MRI), for MPMRI, and for PET/CT, respectively. The overall detection rate proved by histology was 47.4 %. PET/CT provided the highest sensitivity (Sv: 94.4 %) but a lower specificity (Sp: 65.0 %), using MPMRI (Sv: 88.2 %) the specificity increased to 71.4 %. DWIincreased specificity of the native sequences (Sp: 76.2 %). Conventional native sequences plus DWI as well as 3T-MPMRI and PET/CT were same accurate (Acc: 79.0 %) and had similar likelihood ratio (LR: 3.42, 3.03 and 2.62) in detecting unknown PT sites. The accuracy of FDG-PET/CT and MPMRI in case of CUP in finding the primary cancer in the neck regions is identical. While using PET/CT whole body information can be obtained in one examination. MPMRI shows the local soft tissue status more accurately. In cases of CUP PET/CT should be the first method of choice if it is available. MPMRI can clarify the exact primary tumor stage, and it can be advantageous in clarifying the prognostic factors, which is necessary in case of advanced tumor stage and when surgery is under consideration. In case low N stage is likely after the clinical examination and wait and see policy can be considered, MPMRI is recommended, and in this case the significance the of radiation free MPMRI is increasing.
Tài liệu tham khảo
NICE guidelines. Metastatic malignant disease of unknown primary origin: Diagnosis and management of metastatic malignant disease of unknown primary origin. 2010. http://www.nice.org.uk/CG104. Accessed 7 Oct 2016.
Grau C, Johansen IV, Jakobsen J, Geertsen P, Andersen E, Jensen BB. Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish society for head and neck oncology. Radiother Oncol. 2000;55(2):121–9.
Fizazi K, Greco FA, Pavlidis N, Pentheroudakis G. Cancers of unknown primary site: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2011;22:64–8.
Pejšić I, Vrbić S, Todorović M, Petković I, Balić M, Stanković A. Cancer of Unknown Primary Site Syndrome-CUP Syndrome-Diagnostic and Therapeutical Dillemas. Acta Facultatis Medicae Naissensis. 2014;31:87–94. doi:10.2478/afmnai_2014_0010.
Freudenberg LS, Fischer M, Antoch G, Jentzen W, Gutzeit A, Rosenbaum SJ, Bockisch A, Egelhof T. Dual Modality of 18F-FDG PET/CT in Patients with Cervical Carcinoma of Unknown Primary. Med Princ Pract. 2005;14:155–60.
Kostakoglu L. The unknown primary carcinoma. In: Som PM, Curtin HD, editors. Head and neck imaging. 5th ed. New York: Elsevier Mosby; 2011. p. 2841–7.
Wartski M, Le Stanc E, Gontier E, Vilain D, Banal A, Tainturier C, Pecking AP, Alberini JL. In search of an unknown primary tumour presenting with cervical metastases: Performance of hybrid FDG-PET–CT. Nucl Med Commun. 2007;28:365–71.
Licitra L, Felip E. ESMO Guidelines Working Group Squamous cell carcinoma of the head and neck: ESMO Clinical Recommendations for diagnosis, treatment and follow-up. Ann Oncol. 2009;20 Suppl 4:121–2.
Hafidh MA, Lacy PD, Hughes JP, Duffy G, Timon CV. Evaluation of the impact of addition of PET to CT and MR scanning in the staging of patients with head and neck carcinomas. Eur Arch Otorhinolaryngol. 2006;263:853–9.
Rusthoven KE, Koshy M, Paulino AC. The role of fluorodeoxyglucose positron emission tomography in cervical lymph node metastases from an unknown primary tumor. Cancer. 2004;2(101):2641–9.
Grégorie V, Lefebvre J, Licitra L, Felip E. Squamous cell carcinoma of the head and neck: EHNS-ESMO-ESTRO Clinical Practice: Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2010;21:184–6.
Rankin SC. PET in face and neck tumours. Cancer Imaging. 2006;6:105–11.
King AD, Ahuja AT, Yeung DK, Fong DK, Lee YY, Lei KI, Tse GM. Malignant cervical lymphadenopathy: diagnostic accuracy of diffusion – weighted MR Imaging. Radiology. 2007;245:806–13.
Barbero HPM, Jiménez IR, Noguerol TM, Alcalá AL. Utility of MRI diffusion techniques in the evaluation of tumors of the head and neck. Cancers. 2013;5:875–89.
Maeda M, Maier SE. Usefulness of diffusion-weighted imaging and the apparent diffusion coefficient in the assessment of head and neck tumors. J Neuroradiol. 2008;35:71–8.
Vandecaveye V, De Keyzer F, Dirix P, Lambrecht M, Nuyts S, Hermans R. Applications of diffusion-weighted magnetic resonance imaging in head and neck squamous cell carcinoma. Neuroradiology. 2010;52:773–84.
Driessen JP, van Kempen PM, van der Heijden GJ, Philippens ME, Pameijer FA, Stegeman I, Terhaard CH, Janssen LM, Grolman W. Diffusion-weighted imaging in head and neck squamous cell carcinomas: a systematic review. Head Neck. 2015;37:440–8. doi:10.1002/hed.23575. Epub 2014 Feb 12.
Wang J, Takashima S, Takayama F, Kawakami S, Saito A, Momose M, Ishiyama T. Head and neck lesions: characterization with diffusion- weighted echo-planar MR imaging. Radiology. 2001;220:621–30.
Harris M, Taylor G. Medical Statistics Made Easy, London & New York: Taylor & Francis, 2nd Edition; 2008; p. 63–66.
Nakamura T, Sumi M. Nodal imaging in the neck: recent advances in US, CT and MR imaging of metastatic nodes. Eur Radiol. 2007;17:1235–41.
Intensity Modulated Radiation Therapy Collaborative Working Group. Intensity-modulated radiotherapy: current status and issues of interest. Int J Radiat Oncol Biol Phys. 2001;51:880–914.
Nuyts S. Defining the target for radiotherapy of head and neck cancer. Cancer Imaging. 2007;7:50–5.
Mendenhall WM, Mancuso AA, Parsons JT, Stringer SP, Cassisi NJ. Diagnostic evaluation of squamous cell carcinoma metastatic to cervical lymph nodes from an unknown head and neck primary site. Head Neck. 1998;20:739–44.
King AD, Vlantis AC, Yuen TW, Law BK, Bhatia KS, Zee BC, Woo JK, Chan AT, Chan KC, Ahuja AT. Detection of nasopharyngeal carcinoma by MR imaging: diagnostic accuracy of MRI compared with endoscopy and endoscopic biopsy based on long-term follow-Up. AJNR Am J Neuroradiol. 2015;36:2380–5. doi:10.3174/ajnr.A4456.
Lapeyre M, Malissard L, Peiffert D, Hoffstetter S, Toussaint B, Renier S, Dolivet G, Geoffrois L, Fichet V, Simon C, Bey P. Cervical lymph node metastasis from an unknown primary: is a tonsillectomy necessary? Int J Radiat Oncol Biol Phys. 1997;39:291–6.
Gődény M. Prognostic factors in advanced pharyngeal and oral cavity cancer; significance of multimodality imaging in terms of 7th edition of TNM. Cancer Imaging. 2014;14:15.
Hermanns R, De Keyzer F, Vandecaveye V, Carp L. Head and neck cancer imaging. 2nd ed. Berlin/Heidelberg: Springer; 2012.
Özel HE. Use of PET in head and neck cancers. Turk Arch Otorhinolaryngol. 2015;53:73–6.
Cammaroto G, Quartuccio N, Sindoni A, Di Mauro F, Caobelli F; Young AIMN Working Group: The role of PET/CT in the management of patients affected by head and neck tumors: a review of the literature. Eur Arch Otorhinolaryngol. 2015; doi: 10.1007/s00405-015-365-4, Berlin /Heidelberg: Springer; 2015.
Sève P, Billotey C, Broussolle C, Dumontet C, Mackey JR. The role of 2-deoxy-2-[F-18] fluoro-D-glucose positron emission tomography in disseminated carcinoma of unknown primary site. Cancer. 2007;109:292–9.
Srinivasan A, Dvorak R, Perni K, Rohrer S, Mukherji SK. Differentiation of benign and malignant pathology in the head and neck using 3T apparent diffusion coefficient values: early experience. AJNR Am J Neuroradiol. 2008;29:40–4.
Srinivasan A, Dvorak R, Rohrer S, Mukherji SK. Initial experience of 3-tesla apparent diffusion coefficient values in characterizing squamous cell carcinomas of the head and neck. Acta Radiol. 2008;49:1079–84.
Kim SK, Choi HJ, Park SY, Lee HY, Seo SS, Yoo CW, Jung DC, Kang S, Cho KS. Additional value of MR/PET fusion compared with PET/CT in the detection of lymph node metastases in cervical cancer patients. Eur J Cancer. 2009;45:2104–9.
Kim KW, Krajewski KM, Jagannathan JP, Nishino M, Shinagare AB, Hornick JL, Ramaiya NH. Cancer of unknown primary sites: What radiologists need to know and what oncologists want to know. AJR Am J Roentgenol. 2013;200:484–92.
Koh DM, Collins DJ. Diffusion-weighted MRI in body: applications and challenges in oncology. AJR Am J Roentgenol. 2007;88:1622–35.
Bhatia KS, King AD, Yeung DK, Mo F, Vlantis AC, Yu KH, Wong JK, Ahuja AT. Can diffusion-weighted imaging distinguish between normal and squamous cell carcinoma of the palatine tonsil? Br J Radiol. 2010;83:753–8.
Mourad WF, Hu KS, Shasha D, Concert C, Ishihara D, Lin W. Initial experience with oropharynx-targeted radiation therapy for metastatic squamous cell carcinoma of unknown primary of the head and neck. Anticancer Res. 2014;34:243–8.
Durmus K, Rangarajan SV, Old MO, Agrawal A, Teknos TN, Ozer E. Transoral robotic approach to carcinoma of unknown primary. Head Neck. 2014;36:848–52.
Haas I, Hoffmann TK, Engers R, Ganzer U. Diagnostic strategies in cervical carcinoma of an unknown primary (CUP). Eur Arch Otorhinolaryngol. 2002;59:325–33.